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European Union (EU) and European Economic Area (EEA) 
countries reported surveillance data on 2009 pan-
demic influenza A(H1N1) cases to the European Centre 
for Disease Prevention and Control (ECDC) through the 
Early Warning and Response System (EWRS) during 
the early phase of the 2009 pandemic. We describe 
the main epidemiological findings and their implica-
tions in respect to the second wave of the 2009 influ-
enza pandemic. Two reporting systems were in place 
(aggregate and case-based) from June to September 
2009 to monitor the evolution of the pandemic. The 
notification rate was assessed through aggregate 
reports. Individual data were analysed retrospectively 
to describe the population affected. The reporting peak 
of the first wave of the 2009 pandemic influenza was 
reached in the first week of August. Transmission was 
travel-related in the early stage and community trans-
mission within EU/EEA countries was reported from 
June 2009. Seventy eight per cent of affected individ-
uals were less than 30 years old. The proportions of 
cases with complications and underlying conditions 
were 3% and 7%, respectively. The most frequent 
underlying medical conditions were chronic lung (37%) 
and cardio-vascular diseases (15%). Complication and 
hospitalisation were both associated with underlying 
conditions regardless of age. The information from the 
first wave of the pandemic produced a basis to deter-
mine risk groups and vaccination strategies before the 
start of the winter wave. Public health recommenda-
tions should be guided by early capture of profiles of 
affected populations through monitoring of infectious 
diseases.
Introduction
When the 2009 influenza A (H1N1) pandemic started 
in April 2009 and first cases appeared in Europe, 
aggregated (number of cases) and case-based 
(patient-based records) reporting systems were rap-
idly implemented by the European Centre for Disease 
Prevention and Control (ECDC), the European Union 
(EU) and the European Economic Area (EEA) coun-
tries to fulfil the reporting requirements of the World 
Health Organization (WHO) and the EU [1]. The Early 
Warning and Response System (EWRS) was used to 
confidentially report aggregated and case-based data 
[2]. The EWRS was primarily designed as a communi-
cation platform and not as surveillance application. 
However, one of the main advantages of the system at 
the beginning of the pandemic was that it relies more 
on a human driven approach to reporting and this 
allowed timely (daily) reporting of aggregated data by 
the EWRS focal points in the EU/EEA countries to ECDC. 
The European data was then rapidly published in the 
ECDC’s daily situation reports [3] to guide and sup-
port the response of the countries and the European 
Commission. Laboratory-confirmed cases of pandemic 
influenza were reported according to the EU case defi-
nition [4] which includes laboratory confirmation by 
PCR, antigen detection and a four-fold rise in influenza 
specific antibodies. A preliminary communication in 
this journal in June 2009, and the 2009 pandemic influ-
enza A(H1N1) individual case reports from 2 June to 10 
August 2009 [5,6], showed that community transmis-
sion had developed in several of the EU/EEA countries 
since the beginning of the epidemic. A large propor-
tion (77%) of cases was reported in children and young 
adults less than 30 years of age. The frequency of 
reported symptoms was 89% for respiratory and 14% 
for gastro-intestinal symptoms and for 10% of pan-
demic influenza cases at least one underlying medical 
condition was reported. A number of reports from indi-
vidual countries show similar data [7-15]. 
The objective of this article is to describe the main 
characteristics and risk factors of pandemic influenza 
cases reported by EU/EEA countries during the first 
pandemic wave from April to September 2009.
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Methods
The investigators extracted two datasets from the 
EWRS to provide numbers and characteristics of 
the populations infected by the pandemic influenza 
virus. Aggregated numbers of 2009 pandemic influ-
enza A(H1N1) virus infections were reported by 30 
EU/EEA countries by notification date from 27 April 
to 22 September 2009. Characteristics of cases were 
described on a weekly basis using case-based data 
reported from 5 May to 22 September 2009 (Figure 1). 
Adoption of a mitigation strategy was defined as the 
point when a country was no longer recommending lab-
oratory tests for all suspected cases and therefore not 
all pandemic influenza cases were reported to national 
public health authorities. 
Aggregated data 
Weekly notification rates were calculated by divid-
ing the weekly aggregated number of cases reported 
by EU/EEA countries by their respective population 
extracted from the Eurostat website in August 2009 
[16]. The weekly denominator only included the popu-
lation of countries for as long as they reported cases 
to ECDC. 
Individual, case-based data
The set of variables reported in the case-based system 
were compiled using the WHO guidance for surveillance 
of human infection with the 2009 pandemic influenza 
A(H1N1) virus [17]. The variables for the characterisa-
tion of the cases were: age, sex, travel-association, 
vital status (alive or dead), dates (notification, onset 
of symptoms, treatment started and death), clinical 
presentation, underlying conditions, complications, 
antiviral treatment and prophylaxis, seasonal influ-
enza vaccination status, and hospitalisation. Trends 
over time were analysed by calendar weeks (week 
starting on Monday).
For cases reported from 5 May to 22 September 2009, 
the proportion of hospitalised cases was calculated 
using a weekly median (by country with an interquartile 
range (IQR) and the 95th percentile), the distribution of 
travel and non travel-associated cases was described 
by week of onset over 22 weeks and geographic area 
visited, age-specific notification rates were calculated 
over the 20 weeks reporting period.
Completeness of reporting was calculated for sex, 
travel-association, antiviral treatment and prophylaxis, 
seasonal influenza vaccination and complication. If no 
data was missing, completeness equalled 100%. It was 
not possible to calculate completeness of reporting for 
underlying condition as there was no option for ‘none’ 
or ‘unknown’ underlying condition (see list below). 
Age distributions were compared between groups 
of persons for the variables, sex, travel-association, 
antiviral treatment or prophylaxis, vaccination status, 
underlying conditions and complications, by using 
two-sample Wilcoxon rank-sum (Mann-Whitney) tests. 
Underlying conditions were reported according to the 
following pre-defined categories: cancer, diabetes 
mellitus, human immunodeficiency virus (HIV) infec-
tion and other immune deficiencies, heart disease, 
seizure disorder, lung disease, pregnancy and malnu-
trition. Underlying conditions could also be reported 
Figure 1
Data for analyses of 2009 pandemic influenza A(H1N1) cases reported through the Early Warning and Response System to 
the European Centre for Disease Prevention and Control by European Union and European Economic Area countries, 27 
April - 22 September 2009 
Aggregated data Case-based data
Overall analyses 
n= 51,768 
27 April - 22 September 2009
n = 11,037a 
5 May - 22 September 2009
Trend over time
By date of notification
n= 51,575 
27 April - 20 September 2009
By date of onset
n= 8.197 
17 April - 20 September 2009
Frequency of symptoms and underlying conditionb
n=5,205 
5 May - 22 September 2009
Risk factor analysis (hospitalisation and complication)c
n= 3,381 
5 May - 22 September 2009 
a No data submitted by Greece and Liechtenstein.
b Cases for 26 countries, cases excluded from United Kingdom (inclusion of the first 301 cases only), Belgium and Slovenia (all cases 
excluded).
c Cases for 18 countries, cases excluded from Austria, Bulgaria, France, Latvia, Poland, Portugal, Romania.
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in a free-text field. When conditions reported in the 
free-text fields matched one of the pre-defined catego-
ries mentioned above, they were re-classified into this 
category. 
Associations between outcomes of pandemic influenza, 
hospitalisation or complications, and the variables sex 
age, fever, respiratory/gastro-intestinal symptoms, 
antiviral treatment or prophylaxis, seasonal influenza 
vaccination status, underlying conditions, were ana-
lysed by unadjusted and adjusted (for other variables) 
logistic regression models using STATA software. 
Interactions between variables were tested by using 
the likelihood ratio test to assess the significance of 
each variable in the model.
Datasets for specific analyses
Figure 1 shows how subsets of data are analysed. 
Analyses related to the epidemiological characteris-
tics of cases reported with pandemic influenza were 
performed on the full dataset (n= 11,037) for most of 
the variables. Frequency of symptoms and underly-
ing conditions were analysed on a subset of data 
(n=5,205) including all cases for countries other than 
the United Kingdom (UK) (inclusion of the first 301 
cases only), Belgium and Slovenia (all cases excluded). 
Seven countries (Austria, Bulgaria, France, Latvia, 
Table 1
Number of cases, notification rate, and hospitalisation rate of 2009 pandemic influenza A(H1N1) cases in European Union 
(EU) and European Economic Area (EEA) countries, 27 April – 22 September 2009
Aggregated reporting 27 April to 









Number of cases 
(individual data)






Inter-quartile interval of median 
weekly hospitalisation propor-
tion (95th percentile, %)
Austria 361 2.06 32 357 - 75(3) 18 – 92 (100)
Belgium 126 0.98 29 124 28 5 0 – 58 (100)
Bulgaria 70 0.44 - 68 37 47(3) 5 – 75 (100)
Cyprus 297 31.4 - 205 27 33 20 – 45 (92)
Czech Republic 281 1.29 - 258 36 19 10 – 38 (63)
Denmark 636 5.53 28 97 28 10 5 – 20 (75)
Estonia 68 2.41 - 68 37 0 0 – 27 (100)
Finland 259 2.33 30 175 31 9 0 – 13 (38)
France 1,125 1.10 28 553 29 80c 19 – 94 (100)
Germany 19,207 11.01 - 704 27 29 14 – 40 (80)
Greece 2,149 9.13 - - - - -
Hungary 206 0.98 33 110 31 13 4 – 32 (75)
Iceland 193 29.33 - 87 34 - -
Ireland 885 10.05 29 174 30 3 0 – 15 (75)
Italy 2,384 1.90 - 134 26 30 20 – 37 (50)
Latvia 30 0.63 - 29 37 47c 0 – 71 (94)
Liechtenstein 5 6.73 - - - - -
Lithuania 51 0.76 - 51 35 15 0 – 36 (86)
Luxembourg 190 18.70 - 267 - 0 0 (19)
Malta 298 34.59 29 105 29 4 0 – 7 (11)
Netherlands 1,473 5.61 33 246 30 0 0 (5)
Norway 1,336 13.43 30 60 31 0 0 – 3 (22)
Poland 164 0.20 35 66 30 100c 67 – 100 (100)
Portugal 2,983 13.38 34 344 34 47c 40 – 66 (89)
Romania 333 0.73 - 331 37 83c 67 – 100 (100)
Slovakia 131 1.15 33 130 37 15 9 – 73 (100)
Slovenia 244 5.74 36 7 26 - -
Spain 1,538 2.61 28 113 20 - -
Sweden 1,274 6.61 29 172 28 0 0 – 11 (21)
United 
Kingdom 1,3471 10.48 30 6,002 26 1 0 – 2 (5)
EU/EEA 51,768 5.33 11,037 21 13 – 29 (40)
a Cases were reported by date of notification from 27 April to 22 September 2009.
b Cases were reported by date of notification from 5 May to 22 September and by date of onset from 19 April to 20 September 2009.
c Countries with high hospitalisation rate. 
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Poland, Portugal, Romania) where hospitalisation was 
performed mainly for isolation purposes, leading to 
an over-representation of mild cases among hospital-
ised cases, were not included in risk factor analyses 
(n=1,748).
Results 
Aggregated data - weekly notification rates
In total, 51,768 confirmed cases of pandemic influenza 
were reported as aggregated case reports by all EU/
EEA countries. The weekly notification rate was cal-
culated for the 51,575 cases reported from 27 April to 
20 September 2009 (Figure 1). It increased from week 
18 to week 27 (end of June) where it peaked with eight 
cases per million population. A second peak in the 
weekly notification rate was observed in week 32, in 
early August, with 13.6 cases per million population, 
and was followed by a decrease from week 33, when 
countries progressively adopted mitigation strategies 
(Table 1, Figure 2). 
The population used as a denominator for the weekly 
notification rate decreased after week 29, when coun-
tries stopped reporting pandemic influenza cases to 
ECDC. 
The average weekly notification rate over the period 
described above was greater than 10 per million pop-
ulation in Cyprus, Germany, Iceland, Luxembourg, 
Malta, Norway, Portugal and the UK.
Case-based data
A cumulative number of 11,037 cases of pandemic 
influenza were reported as individual reports by 28 
EU/EEA countries (no data submitted by Greece and 
Liechtenstein) from 5 May to 22 September 2009 (Table 
1).The number of cases reported by the UK accounts 
for more than half (54%) of the individual case reports. 
Germany and France reported more than 500 cases; 
Spain stopped reporting individual cases before the 
end of June 2009. Data by week of onset were avail-
able for 8,197 (74%) cases. The weekly distribution of 
individual cases reported by date of onset of symp-
toms peaked in week 25 (mid-end June) with 1,684 
cases reported in week 25 and 1,549 in week 26. The 
decreasing numbers observed after week 26 and until 
September 2009 can be explained by the fact that the 
UK, followed by other countries stopped reporting indi-
vidual cases to ECDC (Figure 3). 
Travel-associated cases
Of 10,643 cases with travel-related information i.e. 
having been outside the country of notification dur-
ing the incubation period, 7,101 (67%) were reported 
as domestic cases i.e. having acquired the infection in 
the country where they were reported. Data on travel 
history and week of onset of symptoms were available 
for 7,974 cases (75% of cases with travel-related infor-
mation) and among those, 3,333 had travelled abroad. 
The proportion of travel-associated pandemic influ-
enza cases was 100% in week 16 and decreased pro-
gressively to 19% in week 25, when the total number 
of reported cases was highest. In week 25, a large pro-
portion of cases were reported as community-acquired 
by the UK. The proportion of travel-associated cases 
increased again after week 25 and remained above 50 % 
until week 37. Large proportions had travelled to North 
America (1,314 cases, 39%) or within EU/EEA countries 
(1,528 cases, 46%). At the start of the pandemic, dur-
ing weeks 16 to 23, almost all travel-associated cases 
(≥92%) were linked to travel to North America, and 
this was gradually replaced by travel within EU/EEA 
countries after week 24 and, from week 31 to week 38, 
almost all travel-associated cases were reported within 
EU/EEA countries (≥83%). The percentage of cases who 
had travelled to other continents was 6% or less: 159 of 
3,333 cases (5%) returned from Asia, 130 (4%) returned 
from South America and 99 (3%) returned from another 
country, mainly Australia. 
Hospitalised cases
The median of the weekly percentage of hospitalised 
cases by country was 21% with an IQR of 13 to 29% 
and a 95th percentile of 40% in 25 EU/EEA countries. 
Information on hospitalisation was not reported by 
Iceland, Spain and Slovenia (Table 1). Seven coun-
tries were identified with a median proportion of hos-
pitalised cases greater than 40 % (95th percentile): 
Austria, Bulgaria, France, Latvia, Poland, Portugal and 
Romania. These countries had similarly high hospi-
talisation rates during their containment phase of the 
pandemic which decreased when hospitalisation was 
no longer recommended for isolation purposes in these 
countries. 
Age, sex and antiviral treatment 
In 28 EU/EEA countries, children and young adults 
less than 30 years of age represented 78% (n=10,846) 
of cases reported and the highest age-specific 
Figure 2
2009 pandemic influenza A(H1N1) notification rate (per 
million population, n=51,575) and population of reporting 
European Union and European Economic Area countries 
by week of report, 27 April (week 18) – 20 September 
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EEA: European Economic Area; EU: European Union
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notification rate was observed in the age group 10 to 
14 years  with 7.7 per 100,000 population (Figure 4). 
Two peaks were observed in those under 30 years of 
age: the first peak, in 10 to 14 year-olds, corresponded 
to a series of school outbreaks reported for example 
in the UK and Germany [7,8]. The second peak was 
Figure 4
Age-specific notification rate of 2009 pandemic influenza A(H1N1) cases reported by 28 European Union and European 




















































a 212 cases are reported below 1-year-old with an age-specific rate of 4 per 100,000 population.
Figure 3
Total (n=7,974), domestic (n=4,641) and travel-associated (3,333) cases of 2009 pandemic influenza A(H1N1) virus infection 
in European Union and European Economic Area countries by week of onset and continent of travel, 19 April (week 16) – 


























EEA: European Economic Area ; EU: European Union.
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attributed to a higher number of travel-associated 
cases in 20 to 24 year-olds. A decreasing trend over 
time in the notification rate was observed in individu-
als aged over 29 years (Figure 4). Five age groups were 
Figure 5
Underlying conditions of 2009 pandemic influenza A(H1N1) cases reported in 26 European Union and European Economic 
Area countries, 5 May – 22 September 2009 (n=331) 
















































HIV: Human immunodeficience virus.
a Include 33 cases reported with asthma as a text field.
b Include cases reported with other conditions: hypertension, lung disease, kidney disorder, obesity.
c Include cases reported with other conditions: hypertension, asthma, obesity.
d Include cases reported with other conditions: seizure and/or diabetes and/or other condition.
e Reported as text field.
Table 2
Characteristics of 2009 pandemic influenza A(H1N1) cases reported in 28 European Union and European Economic Area 
countries (n=11,037, except for underlying conditions, n=5,205), 5 May – 22 September 2009
Variables Category Number of cases (%) Completeness %
Age
Median age % 0-9 % 10-19 % 20-29 % 30-59 % ≥60
Sex M 5,224 (53) 89 19 19 32 28 20 2
F 4,648 20 18 31 27 23 2
Travel-associated Y 3,542 (33) 96 24 8 22 39 28 2
N 7,101 14 26 37 20 16 1
Treatment Antiviral 2,440 (26) 85 22 12 28 33 25 2
Other 2,759 (29) 15 25 34 22 17 1
N 4,193 (45) 16 24 33 23 18 1
Prophylaxis 110 (4) 28 21 17 26 26 28 3
Vaccination against 
seasonal influenza 263 (3) 81 28 9 17 25 36 12
Complication 94 (3) 26 26 10 19 28 37 6
Underlying conditiona 343 (7) - 28 8 23 21 38 10
F: female; M: male; N: no; Y: yes
a It was not possible to calculate the proportion of completeness for underlying condition as the category ‘none’ did not exist for this variable.
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further analysed: 0 to 9 years (20% of all cases), 10 
to19 years (32%), 20 to 29 years (26%), 30 to 59 years 
(20%), and over 60 years (2%).
Table 2 describes the pandemic influenza cases, 
completeness of reporting, median age and distribu-
tion by age group for the variables defined above. 
Completeness of reporting was over 80% for all vari-
ables except antiviral prophylaxis (28%) and complica-
tion (26 %).
The male-to-female ratio was 1.1 (n=9,872 cases with 
available information). The median age of pandemic 
influenza cases was significantly higher among those 
who had travelled abroad (24 years) than among 
domestic cases (14 years), (z=-31.4, p<0.001). Forty-
five per cent (n=9,392) of cases did not receive any 
antiviral treatment, 26% (2,415) received oseltamivir, 
0.3% (25) zanamivir and 29% (2,759) another treat-
ment which was specified in 104 (4%) persons only, 
66 of those had received antibiotics. As expected, 
the proportion of patients who received oseltamivir 
was significantly higher among hospitalised cases 
(74%) compared with non-hospitalised cases (18%). 
Prophylaxis was administered to 4% (110 of 3139 
cases) and previous vaccination for seasonal influenza 
was reported for 3% (264 of 8,913 cases). Seventy-
two of 262 cases (28%) with available information on 
vaccination and underlying condition had at least one 
underlying condition. Complication(s) were reported 
in 3% (94 of 2,878 cases with available information). 
Sixty persons (2%) were reported with pneumonia, 25 
(0.8%) with other respiratory infections, and six with 
non-specified complications. 
Symptoms and underlying conditions
Frequencies of symptoms were calculated based 
on 4,452 cases, after exclusion of 753 (14%) cases 
reported without any symptom. Fever was reported 
in 87%, respiratory symptoms were reported in 85%, 
gastro-intestinal symptoms in 18%, and for 27% of 
cases other symptoms, mainly fatigue or asthenia, 
chill, loss of appetite were noted. The proportion of 
gastro-enteritis was 26 % among children aged less 
than 10 years.
Three hundred and forty-three of 5,205 (7%) pandemic 
influenza cases were reported with at least one under-
lying condition. Underlying conditions were specified 
in 331 (96%) of them. They were described as free 
text for 137 (41%) cases. The most common underly-
ing conditions were unspecified chronic lung diseases, 
including asthma (124 cases, 37%). Other underlying 
conditions reported and associated or not with other 
conditions, were cardiovascular-diseases, diabetes, 
gastro-intestinal diseases, allergy, liver or kidney 
related conditions, neurological disorders, cancer, HIV. 
Pregnancy was reported in 14 women (4%) (Figure 5). 
Epidemiological characteristics and outcomes 
For analyses of associations between hospitalisation 
and potential risk factors the age group 10 to 19 years 
was chosen as reference group as it had the high-
est age-specific notification rate. Univariate analysis 
shows that factors associated with hospitalisation are 
underlying condition (Odds ratio (OR) 1.95, 95% confi-
dence interval (CI) 1.00-2.73), seasonal influenza vac-
cination (OR 1.59, 95% CI 1.04-2.41), and age group 20 
to 29 years (OR 1.32, 95% CI 1.00-1.74). In the multivari-
ate model only underlying condition remained associ-
ated with hospitalisation (OR 1.61, 95% CI 1.07-2.43). 
Analysis of associations between complications and 
potential risk factors for complications were performed 
on data reported by 25 countries (n=2,878, no data 
reported on complication by Belgium, Slovenia and 
Spain). Univariate analysis shows that factors asso-
ciated with complication were: age groups 30 to 59 
years (OR 2.1, 95% CI 1.22-3.88) and over 60 years (OR 
4.13, 95% CI 1.58-10.8) and underlying condition (OR 
3.65, 95% CI 2.24-5.95). In the multivariate model only 
underlying condition remained associated with compli-
cation (OR 3.18, 95% 1.91-5.27).
Discussion
The pandemic influenza cases reported in this article 
characterise the first wave of the 2009 pandemic in 
EU/EEA countries. They include a large proportion of 
travel-related cases that are not necessarily represent-
ative of the population affected by the pandemic dur-
ing the following winter wave. Also representativeness 
of data varied between countries. The weekly notifica-
tion rate calculated for aggregated data is a proxy for 
the notification rate of pandemic influenza over the 
summer months of 2009. Two peaks were observed: 
one in week 26 and one in week 31. The first is proba-
bly due to a reporting artefact in week 26, when a large 
number of cases from previous weeks were reported by 
the UK. The second peak marks the maximum number 
of cases reported during the first pandemic wave in EU/
EEA countries. The sentinel surveillance of influenza-
like illness (ILI) and acute respiratory infections (ARI) 
also showed two peaks at a time similar to that of the 
reporting data: one in week 25 and one in week 31 [18]. 
High notification rates in specific countries like Cyprus 
and Malta can probably be explained by an increase of 
their population during the summer holiday season that 
could not be taken into account in the denominator.
The reported percentage of hospitalised patients in 
(21%) seems extremely high. At the beginning of the 
pandemic, hospitalisation was used for isolation pur-
poses in some countries and this may have inflated 
the percentage rather than a high number of severe 
cases. In the Netherlands, a country that did not rec-
ommend hospitalisation for isolation purposes, a hos-
pitalisation rate of only 2.2% (35 of 1,622 patients with 
confirmed pandemic influenza) was reported until 14 
August 2009, when a change in notification criteria to 
only hospitalised patients was implemented [19].
Case-based data was available for merely 21% of the 
reported aggregated cases. However, this was expected 
because the purpose of the case-based system was to 
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capture the first few hundred cases of pandemic influ-
enza reported in all Member States, while case-based 
reporting was still feasible. This purpose was achieved 
in most countries that have reported more than 100 
cases in the aggregated reports. 
Table 3
Univariate and multivariate analysis for factors influencing hospitalisation and complications of 2009 pandemic influenza 






















Gender Male 1,609 13% 1 – – 1,563 3% 1 – –
Female 1,380 14% 1.12 0.91 1.38 1,297 4% 1.16 0.77 1.75
Age 0–9 353 14% 1.21 0.81 1.8 318 3% 1.26 0.56 2.84
10–19 963 11% 1 – – 766 2% 1 – –
20–29 1,027 15% 1.32 1 1.74 961 3% 1.2 0.65 2.21
30–59 915 14% 1.23 0.93 1.65 732 5% 2.1 1.22 3.88
≥=60 72 11% 0.83 0.39 1.76 69 9% 4.13 1.58 10.8
Treatment Yes 1,447 14% 1.25 0.96 1.63 1,770 4% 1.21 0.75 1.96
No 783 11% 1 – – 754 3% 1 – –
Prophylaxis Yes 83 18% 1.43 0.8 2.54 59 2% 0.47 0.06 3.43
No 1,658 13% 1 – – 2,255 4% 1 – –
Vaccination Yes 156 19% 1.59 1.04 2.41 171 6%
No 1,909 13% 1 – – 1,840 3% 1 – –
Underlying Yes 222 22% 1.95 1 2.73 250 9% 3.65 2.24 5.95
conditions No 2,778 13% 1 – – 2,628 3% 1 – –
Multivariate analysis
Age 0–9 – – 0.92 0.58 1.47 – – 1.06 0.49 2.3
10–19 – – 0.77 0.55 1.06 – – 0.86 0.46 1.58
20–29 – – 1 – – – – 1 – –
30–59 – – 0.85 0.61 1.18 – – 1.67 0.99 2.81
≥60 – – 0.51 0.21 1.26 – – 2.32 0.89 6.05
Vaccination Yes – – 1.48 0.95 2.33 – – – – –
No – – – – – – – – –
Underlying Yes – – 1.61 1.07 2.43 – – 3.18 1.91 5.27
conditions No – – 1 – – – – 1 – –
OR: Odds ratio.
Table 4
Percentage of underlying and co-morbid conditions reported in studies performed among patients hospitalised with 2009 
pandemic influenza A(H1N1)
Study Number of patients Chronic lung disease, including asthma Cardio-vascular disease Diabetes Obesity Pregnancy
US [11] 272 36% 13% 15% - 7%
US, California 
[12] 1,088 37% 15% 11% 48% 10%
Canadaa [13] 168 32%b 15% 21% 33% 8%
Australia & New 
Zealanda [14] 722 33% 11%
c 16% 29% 9%
Mexicoa [15] 58 7% 10%d 17% 36% n.a.
EU/EEA 331 37 % 15% 9% 4%
EEA: European Economic Area; EU: European Union; US: United States. 
a Patients hospitalised in critical care units. 
b Asthma and/or chronic obstructive pulmonary disease.
c Only chronic heart failure.
d Arrhythmia and valvular heart diseases.
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The completeness of data for prophylaxis (28%) and 
complication (26%) was low. This can be interpreted in 
two different ways: either the missing information cor-
responds to ‘no prophylaxis’ or ‘no complication’, or to 
unknown information. As we chose to remove missing 
values from the denominator, proportions of persons 
who have received prophylaxis or with complication(s) 
may be over-estimated in our analysis. 
Clinical presentations of patients reported in our sys-
tem are similar to those listed in a review (WHO consul-
tation) of clinical aspects of 2009 pandemic influenza 
[20]. In September 2009, the number of cases reported 
without any symptom was considered as quite high 
(14%) as information about the proportion of asympto-
matic cases was still scares at that time. Asymptomatic 
cases when reported in the context of tracing contacts 
during the containment phase could have been under-
estimated if contact tracing was not systematically 
performed. 
However, it is not known if these cases were really 
asymptomatic or if symptoms were not reported. In 
the latter case, 14% would be an over-estimation of 
the proportion of asymptomatic cases. Serological 
surveys are the only way to estimate the proportion of 
asymptomatic 2009 pandemic influenza cases. In the 
meanwhile, results from such studies suggest that a 
considerable number of those infected with pandemic 
influenza A(H1N1) virus may have been asymptomatic 
[21,22].
The overall proportion of underlying conditions (7%) 
reported in our dataset is similar to the information 
reported by WHO for Ontario, Canada in June 2009 [23]. 
We compared proportions of underlying conditions with 
results from other studies among hospitalised patients 
with pandemic influenza in the United States [24,25], 
Canada [26], New Zealand [27] and Mexico [28] (Table 
4). Although not necessarily all cases reported with 
underlying conditions in our dataset were hospital-
ised, the proportion of chronic lung diseases (including 
asthma) and cardio-vascular diseases among hospital-
ised patients were similar to those reported elsewhere 
[24-27]. However, the proportions of cases reported 
with metabolic conditions (diabetes and obesity) and 
pregnancy are lower in EU/EEA countries than those 
reported in hospitalised patients in the countries men-
tioned above. In our dataset, patients with underly-
ing conditions were more likely to be hospitalised and 
underlying conditions were associated with complica-
tions regardless of age.
The fact that 45% of our cases did not receive any 
treatment may either indicate that they did not have 
a severe condition or it may reflect the treatment poli-
cies in the countries who may have only recommended 
treatment for severely ill. 
Most cases were found in younger or middle-aged age 
groups. Above the age of 60, there was a steep decline 
in the number of pandemic influenza A(H1N1) cases. 
This could be related to previous exposure of individu-
als over 60 years to influenza A(H1N1) viral strains cir-
culating after the 1918 pandemic until the 1950s [29]. 
Recent  sero-surveys conducted in the UK [30] and in 
Finland [31] support this hypothesis.
Only three deaths were reported in the individual 
case data, this contrasts with the 159 deaths reported 
in EU/EEA countries in the ECDC situation report of 
22 September 2009 [3]. Information about deaths is 
essential to assess severity of the disease appropri-
ately. Additional monitoring systems are needed to col-
lect this type of information in a timely manner. 
Conclusion
The primary focus of this article was to present the 
case-based data collected during the first phase of the 
pandemic in EU/EEA countries and their implications 
for rapid public health action. The case-based report-
ing system was stopped in September 2010, due to the 
associated heavy work load and the high numbers of 
affected people. Case-based data were not collected in 
the population-based system during the second phase 
of the pandemic and thus our data cannot be used 
for comparison between the two waves. Overall, our 
results are in line with other observations that the early 
phase of the pandemic mainly affected children and 
young adults in European countries [7-15]. Individuals 
infected with 2009 pandemic influenza A(H1N1) and 
with underlying condition(s) were more likely to be hos-
pitalised or to develop (severe) complications regard-
less of their age, particularly those with underlying 
respiratory diseases. The epidemiological information 
collected during the first wave of the pandemic pro-
vided some initial indication to determine risk groups 
and vaccination strategies. In the early phase of the 
pandemic, results from serological studies would have 
been helpful to determine if and to what extent individ-
uals over 60 years have pre-existing immunity against 
pandemic 2009 pandemic influenza A(H1N1) from H1N1 
strains circulating after the 1918 pandemic up until the 
1950s. Our reporting system provided baseline data 
and helped to guide initial public health recommen-
dations, however, as the profile of the affected popu-
lation may have changed over time it is important to 
continue monitoring. The initial surveillance system 
was followed by a case-based reporting system of 
severe acute respiratory infections among influenza 
cases. Both systems provided timely information of 
public health relevance about profiles of populations 
affected by 2009 pandemic influenza.
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